Login to Your Account

FDA's Response Letter Appears Positive For BioMarin, Genzyme

By Kim Coghill

Thursday, January 30, 2003
Two weeks after a positive FDA advisory panel hearing, Genzyme General and partner BioMarin Pharmaceutical Inc. said Wednesday the agency issued a complete response letter for Aldurazyme without requesting additional clinical data for final approval. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription